Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in the US. Two thirds of cases are cured with standard chemoimmunotherapy. However, patients with high risk features or patients with refractory or relapsed DLBCL (R/R DLBCL)have a 5-year overall survival rate of only 33%.1 Double hit or high grade B cell lymphomas or R/R DLBCL are clinically challenging to manage with 35% overall survival at 2 years despite modern therapies. Thus, finding novel innovative approaches to improve these numbers is an important unmet need. Specific Aim 1: Optimization of a nanoparticle platform for CpG delivery for the treatment of lymphoma Sub-aim 1.1: To engineer an optimized stable Class C CpG NP and screen for maximum anti-lymphoma effects in vitro. Sub-aim 1.2: To determine if class C tmCpG NPs can trigger a systemic anti-tumor immune response Specific Aim 2: To evaluate photothermal therapy using hollow gold nanoshells (HGNs) as an in situ vaccination method for lymphoma therapy
|Effective start/end date||7/1/20 → 6/30/22|
- Lymphoma Research Foundation (Agmt 3/13/20)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.